Skip to content
Optellum
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales
  • Toggle website search
Menu Close
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales
  • Toggle website search

News & Events

Optellum Joins J&J’s Lung Cancer Initiative

  • Post author:Rhiannon Lassiter
  • Post published:August 23, 2021
  • Post category:Media

Reporter: Reed Miller reed.miller@informa.com
MedTech Insight

Read more articles

Previous PostOptellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson applying AI to transform early lung cancer treatment
Next PostOptellum, Johnson & Johnson Collaborate on AI-Powered Lung-Health Initiative

You Might Also Like

Read more about the article PRESS RELEASE: GE Healthcare and Optellum Join Forces to Advance Lung Cancer Diagnosis with Artificial Intelligence

PRESS RELEASE: GE Healthcare and Optellum Join Forces to Advance Lung Cancer Diagnosis with Artificial Intelligence

November 26, 2021
Read more about the article PRESS RELEASE: Optellum Announces Strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson, Applying AI to Transform Early Lung Cancer Treatment

PRESS RELEASE: Optellum Announces Strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson, Applying AI to Transform Early Lung Cancer Treatment

August 18, 2021
Read more about the article First Edition: Aug. 19, 2021

First Edition: Aug. 19, 2021

August 19, 2021
  • Back to News & Events

Recent Posts

  • Breathing Easier: How AI Is Aiding in Identifying the World’s Deadliest Cancer
  • It’s Time to Get Serious About Incidental Lung Cancer Detection
  • PRESS RELEASE: Optellum’s Clinical Partners Present at ATS International Conference 2023
  • Optellum technology can help to determine more cost-effective intervals for lung cancer screening
  • Václav Potěšil, Founder and Chief Business Officer, interviewed by TechRound

Our Mission

Optellum was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, and cured.  Our vision is to redefine early intervention of diseases like lung cancer, by enabling every clinician, in every hospital, to make the right decisions and give their patients the best chance to fight back.

Optellum Ltd.

  • Oxford Centre for Innovation
    Oxford, OX1 1BY
    United Kingdom
  • info@optellum.comOpens in your application

Optellum Inc.

  • TMC Innovation Institute
    2450 Holcombe Blvd, Suite X
    Houston, TX 77021
    United States

Pages

  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

Follow Us

  • Opens in a new tab
  • Opens in a new tab

Certifications

Copyright 2023 - Optellum Ltd | Privacy Policy
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}